165 related articles for article (PubMed ID: 9310277)
1. Effects of ranolazine on ischemic threshold, coronary sinus blood flow, and myocardial metabolism in coronary artery disease.
Bagger JP; Bøtker HE; Thomassen A; Nielsen TT
Cardiovasc Drugs Ther; 1997 Jul; 11(3):479-84. PubMed ID: 9310277
[TBL] [Abstract][Full Text] [Related]
2. Antiischemic and metabolic effects of glutamate during pacing in patients with stable angina pectoris secondary to either coronary artery disease or syndrome X.
Thomassen A; Nielsen TT; Bagger JP; Pedersen AK; Henningsen P
Am J Cardiol; 1991 Aug; 68(4):291-5. PubMed ID: 1858669
[TBL] [Abstract][Full Text] [Related]
3. Metabolic and hemodynamic effects of nicardipine during pacing-induced angina pectoris.
Thomassen A; Bagger JP; Nielsen TT; Henningsen P
Am J Cardiol; 1987 Feb; 59(4):219-24. PubMed ID: 3812268
[TBL] [Abstract][Full Text] [Related]
4. A comparison between ranolazine and CVT-4325, a novel inhibitor of fatty acid oxidation, on cardiac metabolism and left ventricular function in rat isolated perfused heart during ischemia and reperfusion.
Wang P; Fraser H; Lloyd SG; McVeigh JJ; Belardinelli L; Chatham JC
J Pharmacol Exp Ther; 2007 Apr; 321(1):213-20. PubMed ID: 17202401
[TBL] [Abstract][Full Text] [Related]
5. Effects of low-dose dobutamine on coronary hemodynamics, myocardial metabolism, and anginal threshold in patients with coronary artery disease.
Pacold I; Kleinman B; Gunnar R; Loeb HS
Circulation; 1983 Nov; 68(5):1044-50. PubMed ID: 6616788
[TBL] [Abstract][Full Text] [Related]
6. Cardiac metabolic effects of heparin differentiate between patients with normal and stenotic coronary arteries.
Thomassen A; Nielsen TT; Bagger JP; Henningsen P
Int J Cardiol; 1990 Apr; 27(1):37-46. PubMed ID: 1970807
[TBL] [Abstract][Full Text] [Related]
7. Antianginal and cardiac metabolic effects of low-dose glucose infusion during pacing in patients with and without coronary artery disease.
Thomassen A; Nielsen TT; Bagger JP; Henningsen P
Am Heart J; 1989 Jul; 118(1):25-32. PubMed ID: 2662729
[TBL] [Abstract][Full Text] [Related]
8. Improved myocardial lactate extraction after propranolol in coronary artery disease: effected by peripheral glutamate and free fatty acid metabolism.
Nielsen TT; Bagger JP; Thomassen A
Br Heart J; 1986 Feb; 55(2):140-7. PubMed ID: 3942648
[TBL] [Abstract][Full Text] [Related]
9. Altered global myocardial substrate preference at rest and during pacing in coronary artery disease with stable angina pectoris.
Thomassen A; Bagger JP; Nielsen TT; Henningsen P
Am J Cardiol; 1988 Oct; 62(10 Pt 1):686-93. PubMed ID: 3421165
[TBL] [Abstract][Full Text] [Related]
10. Cardiac metabolic and hemodynamic effects of insulin in patients with coronary artery disease.
Thomassen A; Nielsen TT; Bagger JP; Henningsen P
Diabetes; 1989 Sep; 38(9):1175-80. PubMed ID: 2670646
[TBL] [Abstract][Full Text] [Related]
11. Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat.
Zacharowski K; Blackburn B; Thiemermann C
Eur J Pharmacol; 2001 Apr; 418(1-2):105-10. PubMed ID: 11334871
[TBL] [Abstract][Full Text] [Related]
12. Partial fatty acid oxidation inhibitors for stable angina.
Stanley WC
Expert Opin Investig Drugs; 2002 May; 11(5):615-29. PubMed ID: 11996644
[TBL] [Abstract][Full Text] [Related]
13. The effect of verapamil on myocardial exchange of free fatty acids, citrate, lactate and glucose in coronary artery disease.
Bagger JP; Nielsen TT; Henningsen P
Eur Heart J; 1983 Jun; 4(6):406-14. PubMed ID: 6617687
[TBL] [Abstract][Full Text] [Related]
14. Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with beta-blocker or diltiazem.
Cocco G; Rousseau MF; Bouvy T; Cheron P; Williams G; Detry JM; Pouleur H
J Cardiovasc Pharmacol; 1992 Jul; 20(1):131-8. PubMed ID: 1383622
[TBL] [Abstract][Full Text] [Related]
15. Influence of nifedipine on coronary haemodynamics and myocardial metabolism in coronary artery disease.
Bagger JP; Nielsen TT
Eur Heart J; 1985 Jan; 6(1):75-84. PubMed ID: 4006961
[TBL] [Abstract][Full Text] [Related]
16. Ranolazine, a partial fatty acid oxidation inhibitor, its potential benefit in angina and other cardiovascular disorders.
Bhandari B; Subramanian L
Recent Pat Cardiovasc Drug Discov; 2007 Jan; 2(1):35-9. PubMed ID: 18221101
[TBL] [Abstract][Full Text] [Related]
17. Ranolazine: a novel metabolic modulator for the treatment of angina.
McCormack JG; Stanley WC; Wolff AA
Gen Pharmacol; 1998 May; 30(5):639-45. PubMed ID: 9559312
[TBL] [Abstract][Full Text] [Related]
18. Ranolazine. A metabolic modulator for the treatment of chronic stable angina.
Anderson JR; Nawarskas JJ
Cardiol Rev; 2005; 13(4):202-10. PubMed ID: 15949056
[TBL] [Abstract][Full Text] [Related]
19. Ranolazine, a novel anti-anginal agent, does not alter isosorbide dinitrate- or sildenafil-induced changes in blood pressure in conscious dogs.
Zhao G; Messina E; Xu X; Ochoa M; Serpillon S; Shryock J; Belardinelli L; Hintze TH
Eur J Pharmacol; 2006 Jul; 541(3):171-6. PubMed ID: 16777088
[TBL] [Abstract][Full Text] [Related]
20. Ranolazine: a potential new treatment for chronic stable angina.
Anderson JR; Khou S; Nawarskas JJ
Heart Dis; 2001; 3(4):263-9. PubMed ID: 11975803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
